Eli Lilly Doesn't Want to be Seen as 'Just an Obesity Company'
Dow Jones08-06
1251 ET - Eli Lilly has emerged as a leader in the GLP-1 space, with successful weight-loss drugs such as Mounjaro and Zepbound driving results in the recent quarter. "But we're not just an obesity company," CEO David Ricks says on CNBC. "We're also building out a really strong oncology business, and our neuroscience franchise…is doing well." Ricks says he's pleased but not satisfied, as he looks to build value for the future with a strong pipeline as well as investments in business development.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments